immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more
immatics biotechnologies GmbH (IMTXW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.064x
Based on the latest financial reports, immatics biotechnologies GmbH (IMTXW) has a cash flow conversion efficiency ratio of -0.064x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-34.21 Million) by net assets ($536.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
immatics biotechnologies GmbH - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how immatics biotechnologies GmbH's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
immatics biotechnologies GmbH Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of immatics biotechnologies GmbH ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LCS Imobiliar SA
RO:LCSI
|
N/A |
|
KLASSIK RADIO N - Dusseldorf Stock Exchang
DU:KA8
|
N/A |
|
HYPE3F
SA:HYPE3F
|
N/A |
|
Ceylon Tea Services PLC
CM:CTEAN0000
|
N/A |
|
THES. WATER S.+S. EO 112
F:T9W
|
N/A |
|
Sentry Select Primary Metals Corp
TO:PME
|
0.005x |
|
7631
TW:7631
|
0.141x |
|
Derkwoo Electronics Co. Ltd.
KO:263600
|
N/A |
Annual Cash Flow Conversion Efficiency for immatics biotechnologies GmbH (2018–2024)
The table below shows the annual cash flow conversion efficiency of immatics biotechnologies GmbH from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $574.84 Million | $-158.03 Million | -0.275x | -439.47% |
| 2023-12-31 | $225.08 Million | $18.23 Million | 0.081x | -82.76% |
| 2022-12-31 | $213.16 Million | $100.13 Million | 0.470x | +113.82% |
| 2021-12-31 | $24.06 Million | $-81.78 Million | -3.399x | -313.90% |
| 2020-12-31 | $104.26 Million | $-85.61 Million | -0.821x | +52.75% |
| 2019-12-31 | $-40.84 Million | $70.97 Million | -1.738x | +22.94% |
| 2018-12-31 | $-9.17 Million | $20.68 Million | -2.255x | -- |